How I Rate AstraZeneca Plc As A ‘Buy And Forget’ Share

Is AstraZeneca plc (LON: AZN) a good share to buy and forget for the long term?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Right now I’m analysing some of the most popular companies in the FTSE 100 to establish if they are attractive long-term buy and forget investments.

Today I’m looking at AstraZeneca (LSE: AZN) (NYSE: AZN.US)

What is the sustainable competitive advantage?

At the end of 2012, AstraZeneca was one of the largest pharmaceutical companies in the world, employing over 50,000 people worldwide. Furthermore, AstraZeneca’s Crestor treatment is the world’s eighth bestselling drug, with sales of around $6.3bn.

Indeed, due to its size, AstraZeneca has a certain dominance over the biotechnology market, as many smaller competitors cannot compete with the firm’s financial power and research capabilities.  

Additionally, as AstraZeneca has exclusive production rights for its own treatments, the company can set prices, giving itself a wide profit margin. In particular, even after the loss of some exclusive manufacturing rights last year (which caused a 15% drop in revenue), AstraZeneca’s net profit margin still came in at 22%.

Having said that, AstraZeneca is facing fierce competition from generic producers, which are now manufacturing cheaper versions of some key drugs, after the company’s exclusive manufacturing rights expired last year.

Nonetheless, AstraZeneca’s size and global exposure mean that the company is able to stay ahead of the game, as the firm’s brand attracts talented personal.

Moreover, many larger pharmaceutical companies are now forming research partnerships, in an attempt to offset the stream of patent expirations that are affecting the industry.

Company’s long-term outlook?

With the spectre of disease always present, the demand for AstraZeneca’s products will remain constant, or even grow over the long term, as long as the company can produce treatments that are effective.

It appears that AstraZeneca is well placed to do this. Indeed, the firm has 84 new treatments under development, 13 of which are in the final stages of testing.

Furthermore, AstraZeneca has a strong balance sheet with net debt of only $2bn — a debt to asset ratio of 4%, giving the company plenty of room to acquire smaller competitors as well as new treatments for its pipeline.

Foolish summary

Overall, there will always be a strong demand for AstraZeneca’s products and the company has plenty of treatments under development that will allow it to stay ahead of the game. Additionally, with an almost debt free balance sheet, the company has plenty of room to spend for future growth.

So overall, I rate AstraZeneca as a very good share to buy and forget.

More FTSE opportunities

As well as AstraZeneca, I am also positive on the five FTSE shares highlighted within this exclusive wealth report.

Indeed, all five opportunities offer a mix of robust prospects, illustrious histories and dependable dividends, and have just been declared by the Fool as “5 Shares You Can Retire On“!

Just click here for the report — it’s free.

In the meantime, please stay tuned for my next FTSE 100 verdict

> Rupert does not own any share mentioned in this article.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

3 top FTSE 100 value shares I’d buy before August!

These FTSE 100 heavyweight shares have considerable long-term potential. And at current prices, I think they are too cheap to…

Read more »

Investing Articles

Here’s why I’m selling my Lloyds shares to double down on this FTSE 100 stock

Our writer digs into why he prefers HSBC over Lloyds shares right now, despite both performing really strongly in recent…

Read more »

Investing Articles

I’d invest £12,500 in this 1 stock to bag £1K of passive income!

Building a passive income stream through dividends is one of this writer’s biggest ambitions. Here’s how one stock could help.

Read more »

Investing Articles

3 cheap stocks to consider buying for the AI revolution

Investors looking for AI stocks to buy might be worried about high valuations amid current market euphoria, but these three…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Earnings up 20%! But this UK small-cap stock may just be getting started

Are we about to see enduring growth from this UK small-cap business with a rising stock price ahead over the…

Read more »

Investing Articles

1 FTSE 250 stock I’d give a wide berth… for now

One of the worst performers on the FTSE 250 index is a stock that Sumayya Mansoor has decided she won’t…

Read more »

Investing Articles

The FTSE 250 is brimming with potential, especially in stocks like this one

The main Footsie index gets all the attention but its little brother, the FTSE 250, is full of growth potential.…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Investing Articles

What on earth happened to the Premier African Minerals (LSE:PREM) share price?

The Premier African Minerals (LSE:PREM) share price is down a whopping 85% in the last year, so what happened? Gordon…

Read more »